A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

NCT02310763 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

121

Enrollment

INDUSTRY

Sponsor class

Stopped Termination Date 30AUG2018: Reason for termination: Lack of Efficacy

Conditions

Duchenne Muscular Dystrophy

Interventions

BIOLOGICAL: PF-06252616
DRUG: Placebo

Sponsor

Pfizer